Abstract: Intelligent reflecting surface (IRS) is an enabling technology to engineer the radio signal propagation in wireless networks. By smartly tuning the signal reflection via a large number of ...

Abstract: While celebrating the 21st year since the very first IEEE 802.11 “legacy” 2 Mbit/s wireless local area network standard, the latest Wi-Fi newborn is today reaching the finish line, topping ...

PYC Therapeutics (ASX:PYC) has nominated a fourth clinical drug candidate, PYC-002, targeting Phelan-McDermid Syndrome (PMS), a rare neurodevelopmental disorder with no current treatment options. The ...

View PYC Therapeutics Ltd stock forecast data, including PYC stock price estimates and 12-month PYC Therapeutics Ltd price targets, to assess potential upside or downside. Compare PYC analyst ratings ...

PYC Therapeutics kicks off Phase 1b MAD for PKD with first patient dosed in PYC-003; data due CY27, paving the way to registrational Phase 2/3 and NDA. The MAD study aims to establish safety and ...

This raise will set the company up for years. With PYC's value sitting at $944.8 million at the close of trade on Friday, the raise will grow the size of the company by 69.2% in one fell swoop. The ...

PYC Therapeutics, a developer of RNA therapies for genetic diseases and capitalised at $933 million on the ASX, confirmed a $653 million equity raising on Monday morning after Street Talk revealed the ...

A look at the shareholders of PYC Therapeutics Limited (ASX:PYC) can tell us which group is most powerful. The group holding the most number of shares in the company, around 45% to be precise, is ...

Potential PYC Therapeutics Limited (ASX:PYC) shareholders may wish to note that the CEO & Executive Director, Rohan Hockings, recently bought AU$200k worth of stock, paying AU$1.50 for each share.

The S&P/ASX 200 Index is falling on Wednesday, with Flight Centre, Inghams, New Hope Corporation, and PYC Therapeutics shares declining significantly. Both Flight Centre and Inghams' share prices ...

PYC Therapeutics has built a pipeline of drug candidates addressing rare genetic diseases, with three assets now in clinical stages. The company’s strategy centers on using RNA therapeutics to ...